Telehealth Innovation Fueled by Advanced Exosome Therapy – Powered by NextelMed
Investment Highlights
Expanding Telehealth Access
Over 50% of patients face barriers to telehealth. Our platform helps expand access globally.
Rapid Market Growth
The global telehealth market is projected to grow from $285B to over $680B by 2030.
Patent-Protected Innovation
Exosomal NANOG DNA technology enabling early cancer detection and diagnostics.
Clinical-Stage Biotech Assets
Strategic holdings in oncology-focused biotech with strong valuation potential.
Integrated Wellness Platform
Telehealth Injectable Wellness
- GLP-1 weight-management therapies
- Peptide protocols and hormone optimization (e.g., testosterone)
- Fully online intake, consults, and ongoing monitoring
Maxasome Exosomal Nutraceuticals
- Maxasome, Maxasome Plus, Maxasome CBD
- Exosome-enhanced bioavailability
- Targeted for longevity, dermatology, and performance recovery
NANOG DNA Cancer Testing
- Non-invasive saliva-based test concept
- Multi-cancer early detection focus
- Built on exosome/NANOG RNA IP licensed from UCF & Progenicyte
Investment Highlights
Capitalizing on Wellness Trends
The shift toward physician-supervised, outcome-driven wellness solutions is accelerating. Our telehealth platform delivers measurable results in weight loss, performance, and healthy aging while enabling recurring patient engagement and high-margin direct-to-patient models.
Proprietary Maxasome Products
Advanced exosome-based formulations enhance bioavailability and cellular uptake. Designed for targeted demographics, supporting longevity, dermatology applications, and daily performance and recovery for health-conscious individuals.
Patent-Protected Innovation
Exosomal NANOG RNA technology enables early cancer detection at the 1mm level via a non-invasive saliva test, positioning as a disruptive solution in a multi-billion-dollar diagnostics market.
Clinical-Stage Biotech Asset
Strategic holding in Exousia Bio, an oncology-focused biotech developing therapies for Glioblastoma. Backed by Orphan Drug Designation with expansion potential across multiple indications.
Cancer Testing
NANOG DNA Multi-Cancer Testing
- Saliva-based screening concept designed to detect multiple cancers earlier
- Built on exosome and NANOG DNA technology licensed exclusively from UCF
- Targets “silent killer” cancers with a simple, non-invasive approach
Why It Matters
- Cancer diagnostics projected to reach well over $150–200B in the next decade
- Multi-cancer early detection expected to grow rapidly as screening demand increases
- Positions Nextel Medical for significant upside beyond wellness and telehealth
Cancer Testing Intellectual Property
Key Patent
Exosomal NANOG DNA technology (US011193174B2) enables early cancer detection with high accuracy and reliability.
Cancer Testing Intellectual Property
Key Patent
Exosomal NANOG DNA technology (US011193174B2) enables early cancer detection with high accuracy and reliability.
Early Cancer Detection Through a Simple Saliva Test
Our proprietary NANOG DNA-based screening technology enables non-invasive, multi-cancer detection using just a small saliva sample. Designed for high sensitivity and accuracy, it represents a major breakthrough in early diagnosis and preventative care.
Telehealth Injectable Wellness
How It Works
- Complete an online intake form
- Meet with a licensed provider via telehealth
- If appropriate, receive prescriptions and follow an ongoing injectable wellness plan
Key Benefits
- Focused on GLP-1, peptides, and hormone replacement
- At-home convenience with full medical supervision
- Structured for recurring, results-driven treatment plans
Maxasome Exosomal Wellness Products
Maxasome
- Daily exosomal nutraceutical for overall vitality and cellular wellness
- Supports recovery and day-to-day performance
Maxasome Plus
- Higher-intensity formulation for users seeking enhanced performance support
- Designed for active individuals and demanding lifestyles
Maxasome CBD
- Exosomal formulation combined with CBD
- Supports calm, recovery, and stress management
Massive Market Opportunity
The global telehealth market is experiencing rapid growth driven by increased demand for remote healthcare, chronic disease management, and digital health adoption. With strong projections and expanding global reach, this sector represents a significant investment opportunity.
Join the Future of Telehealth & Biotech Innovation
NextelMed combines advanced biotechnology with scalable telehealth solutions, creating a unique investment opportunity. With strong intellectual property and growing market demand, we are positioned for long-term value creation.
Early detection platform focused on innovative, non-invasive diagnostic solutions for better healthcare outcomes